Home Newsfeeds SVB Leerink Maintains Market Perform on Blueprint Medicines, Lowers Price Target to $56

SVB Leerink Maintains Market Perform on Blueprint Medicines, Lowers Price Target to $56

SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Perform and lowers the price target from $60 to $56.

byBenzinga Newsdesk

July 1, 2022

1 minute read

SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Perform and lowers the price target from $60 to $56.

Navigator Holdings Ltd. Announces Additional Vessel Acquisitions Under 60/40 Joint Venture With Greater Bay Gas

By Happy Mohamed

March 27, 8:31 AM

Navigator Holdings Ltd. ("Navigator" or "Company") (NYSE:NVGS), the owner and operator of the world's largest fleet of handysize liquefied gas carriers, is pleased to announce the third and fourth

NVGS

Tapestry Likely To Report Higher Q1 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

By Lisa Levin

November 9, 3:51 AM

Tapestry, Inc. (NYSE: TPR) is projected to release financial results for its fiscal 2024 first quarter, before the opening bell on Nov. 9, 2023.

TPR

Analyst Ratings

7 Analysts Have This to Say About Travelers Companies

By Benzinga Insights

November 1, 3:20 PM

Over the past 3 months, 7 analysts have published their opinion on Travelers Companies (NYSE:TRV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

TRV

Mesoblast’s Lead Drug Candidate Goes Under FDA Priority Review For Bone Marrow Transplant Complications In Kids

By Vandana Singh

March 8, 9:34 AM

Mesoblast Ltd (NASDAQ:MESO) rallied after the FDA agreed to review the company’s lead drug candidate, remestemcel-L, on a priority basis, more…

MESO

SVB Leerink Maintains Market Perform on Blueprint Medicines, Lowers Price Target to $56

Related Posts

Navigator Holdings Ltd. Announces Additional Vessel Acquisitions Under 60/40 Joint Venture With Greater Bay Gas

Tapestry Likely To Report Higher Q1 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

7 Analysts Have This to Say About Travelers Companies

Mesoblast’s Lead Drug Candidate Goes Under FDA Priority Review For Bone Marrow Transplant Complications In Kids